RxDoctor Payments Data

Marie Lippman, MD

Child & Adolescent Psychiatry · Bedford, NYNPI 1295846061

Payments from drug & device makers

$1,126in general payments, 2019–2025

Across 36 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$626
  • Alkermes, Inc.$325
  • Neurocrine Biosciences, Inc.$117
  • Otsuka America Pharmaceutical, Inc.$26
  • Acadia Pharmaceuticals Inc$22
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$1,01590%
  • Education$11110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,126 in reported general payments places this provider in the 75th percentile of 317 child & adolescent psychiatry providers in New York.

See all child & adolescent psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$194,761
Medicare patients
259
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$190,474
AustedoDeutetrabenazine28$161,925
Invega SustennaPaliperidone Palmitate54$149,450
VraylarCariprazine Hcl24$36,480
Risperdal ConstaRisperidone Microspheres36$34,143
Abilify MaintenaAripiprazole12$27,413
Clozapine258$23,260
LybalviOlanzapine/Samidorphan Malate12$20,108
CaplytaLumateperone Tosylate11$18,891
Divalproex Sodium532$11,318
Fluphenazine Hcl82$9,236
Haloperidol249$8,482
NamzaricMemantine Hcl/Donepezil Hcl13$7,986
Memantine Hcl149$7,960
Risperidone428$7,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$117$190,47423 claims
Teva Pharmaceuticals USA, Inc.Austedo$626$161,92528 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$26$27,41312 claims
Alkermes, Inc.Lybalvi$325$20,10812 claims
Lilly USA, LLCOlanzapine$12$7,145533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 317 child & adolescent psychiatry providers in New York.

Other child & adolescent psychiatry in Bedford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →